EASD 2019 — T1D: ADO09 reduces postprandial glucose and leads to slower gastric emptying than lispro


  • Brandon May
  • Conference Reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Treatment with ADO09, a formulation comprising pramlintide and the A21G human insulin analog, was associated with a greater reduction in postprandial blood glucose (ppBG) than insulin lispro in patients with type 1 diabetes (T1D).

Why this matters

  • Some individuals with T1D have difficulties achieving glycemic control using insulin lispro alone.

Study design

  • A total of 24 patients with T1D received either ADO09, 7.5 U human insulin and 45 µg pramlintide (Ins&Pram), or insulin lispro immediately prior to consuming a mixed meal containing 53% carbohydrate.
  • Treatment was combined with 1 g paracetamol to assess gastric emptying.
  • Funding: None reported.

Key results

  • Treatment with ADO09 was associated with >95% reduction in ppBG excursions in the first hour following the meal (mean ± standard deviation ∆AUC blood glucose [BG] 0-1 hour: 1.4±9.9 vs 43.5±15.3 mg*hour/dL; P<.0001>
  • ADO09 was also associated with significant improvement in maximum ppBG (∆BGmax, 87.0±35.5 mg/dL) vs insulin lispro (109.2±31.1 mg/dL; P=.0133) and Ins&Pram (109.4±44.3 mg/dL; P=.0357).
  • ADO09 was similar to Ins&Pram with regard to gastric emptying time (Tmax_paracetamol: 2.30±1.49 vs 2.38±1.36 hours, P=NS) but was significantly slower than insulin lispro (0.76±0.73 hours; P<.0001>
  • Treatments in the study were well tolerated, and adverse events were rare.

Limitations

  • Small sample size.